+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Global Non-Invasive Prenatal Diagnostics Market

  • ID: 2895280
  • Report
  • Region: Global
  • 106 Pages
  • VeracityHealth
1 of 4

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Berry Genomics Co., Ltd
  • CellScape
  • Illumina, Inc.,
  • Kellbenx
  • LifeCodexx AG
  • MORE
The aim of this report was to review recent advances in use of circulating cell-free miRNA, DNA and mRNA as novel biomarkers which can be used as a non-invasive method for prenatal diagnostics. The report will also provide a market analysis of the market value, growth rates and market development as well as examining the dynamics and factors influencing the growth and development of this market. This report also looks at the challenges and potential threats facing the industry, and the factors influencing the market shares of the major market suppliers as well as smaller indigenous manufacturers in local markets.

The data collection and forecasting methods used in the preparation of this report are broadly divided into three methods. These are primary data and information gathering, secondary data and information gathering and market share analysis and market forecast prediction. Information and data including estimates on market values, growth rates and market share data were gathered from the methods described and were incorporated into proprietary computer forecasting and market share analysis models.

The forecast model was used to derive market estimates for future years. It incorporates a rate factor, which helps determine the speed with which the market develops, which is similar to that observed for markets for other medical products and is adjusted to match historic data for the market under analysis.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Ariosa Diagnostics
  • Berry Genomics Co., Ltd
  • CellScape
  • Illumina, Inc.,
  • Kellbenx
  • LifeCodexx AG
  • MORE

Executive Summary
ES.1 Introduction to the Non-invasive Prenatal Diagnostics Market
ES.2 Background to Circulating Nucleic Acids
ES.3 Market Revenue Analysis: Non-invasive Prenatal Diagnostics
ES.4 Market Share Analysis: Non-invasive Prenatal Diagnostics
Exhibit E.S. 1: Global Market Share Analysis – Non-invasive Prenatal Diagnostic Products (2013)
Exhibit E.S. 2: Global Market Share Analysis – Non-invasive Prenatal Diagnostic Products (2013)
ES.5 Company Profiles

Chapter 1: Introduction to the Non- invasive Prenatal Diagnostics Market
1.1 Background to the Report
1.2 Report Objectives and Deliverables
1.3 Methodology

Chapter 2: Background to Circulating Nucleic Acids
2.1 Introduction to Circulating Nucleic Acids (CNAs)
Exhibit 2.1: Major Developments in Understanding Nucleic Acids and their Cellular Roles
Exhibit 2.2: Circulating DNA Concentrations in Blood of Healthy Donors and Selected Cancer Patients
2.2 Categories of Circulating Nucleic Acids
2.2.1 Circulating Cell-Free DNA
2.2.2 Circulating Extracellular DNA
2.2.3 RNA
2.2.3.1 microRNAs (miRNAs)
2.2.3.2 miRNA Mimics and Inhibitors
2.2.3.3 Small Interfering RNA (siRNA)
2.2.3.4 RNA Interference (RNAi)
2.3 Circulating Nucleic Acids as a Diagnostic Tool
2.3.1 Circulating DNA as a Biomarker of Cancer
2.3.2 Use of Circulating DNA for Prenatal Diagnosis
2.3.3 Circulating RNA as a Biomarker of Cancer
Exhibit 2.3: Circulating Tumour-Associated miRNAs as potential biomarkers in Lung Cancer
Exhibit 2.4: Circulating Tumour-Associated miRNAs as potential biomarkers in Breast Cancer
Exhibit 2.5: Circulating Tumour-Associated miRNAs as potential biomarkers in Prostate Cancer
Exhibit 2.6: Circulating Tumour-Associated miRNAs as potential biomarkers in Ovarian Cancer
Exhibit 2.7: Circulating Tumour-Associated miRNAs as potential biomarkers in Bladder Cancer
Exhibit 2.8: Circulating Tumour-Associated miRNAs as potential biomarkers in Pancreatic Cancer
Exhibit 2.9: Circulating Tumour-Associated miRNAs as potential biomarkers in Gastric Cancer
Exhibit 2.10: Circulating Tumour-Associated miRNAs as potential biomarkers in Liver Cancer
Exhibit 2.11: Circulating Tumour-Associated miRNAs as potential biomarkers in Colo-Rectal Cancer
Exhibit 2.12: Circulating Tumour-Associated miRNAs as potential biomarkers in Oral Cancer
Exhibit 2.13: Circulating Tumour-Associated miRNAs as potential biomarkers in Esophageal Cancer
2.3.4 Circulating RNA in Pregnancy
2.4 Methods Used for the Detection of Circulating Nucleic Acids
Exhibit 2.14: Top molecular CNA Characterisation Techniques
Exhibit 2.15: Top molecular CNA Characterisation Techniques

Chapter 3: Market Revenue Analysis: Non- invasive Prenatal Diagnostics
3.1 Introduction
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.1.1 Significant Advantages of Conventional Prenatal Screening and Diagnostic Methods
3.2.1.2 Significant Endorsement for NIPD
3.2.1.3 Recognised Benefits Associated with NIPD
3.2.2 Market Restraints
3.2.2.1 Ethical Challenges in Providing Noninvasive Prenatal Diagnosis
3.2.2.2 Specific Reimbursement and Accessibility Issues
3.2.2.3 Specific Identified Limitations of NIPD
3.3 Selected Non-invasive Prenatal Diagnostic Products
Exhibit 3.1: Featured Non-invasive Prenatal Diagnostic Products
Ariosa Diagnostics
3.4 Market Revenue Analysis
3.4.1 Global Market Revenue Analysis
3.4.2 Global Market Revenue Analysis by Geographic Region
Exhibit 3.2: Global Market Revenue Forecast - Non-invasive Prenatal Diagnostic Products (2010 –2020)
Exhibit 3.3: Global Market Revenue Forecast - Non-invasive Prenatal Diagnostic Products (2010 – 2020)
Exhibit 3.4: Market Revenue Forecast by Geographic Region - Non-invasive Prenatal Diagnostic
Products (2010 – 2020)
Exhibit 3.5: Percentage Share of Global Market Revenue Forecast by Geographic Region - Noninvasive Prenatal Diagnostic Products (2010 – 2020)
Exhibit 3.6: Percentage Share of Global Market Revenue Forecast by Geographic Region - Noninvasive Prenatal Diagnostic Products (2010 – 2020)
3.4.3 Market Revenue Analysis by Selected Country
Exhibit 3.7: Market Revenue Forecast by Selected Countries - Non-invasive Prenatal Diagnostic Products (2010 – 2020)
Exhibit 3.8: Market Revenue Forecast by Selected Countries - Non-invasive Prenatal Diagnostic Products (2010 – 2020)

Chapter 4: Market Share Analysis: Non- invasive Prenatal Diagnostics
4.1 Market Share Analysis
4.1.1 Global Market Share Analysis
Exhibit 4.1: Global Market Share Analysis – Non-invasive Prenatal Diagnostic Products (2013)
Exhibit 4.2: Global Market Share Analysis – Non-invasive Prenatal Diagnostic Products (2013)
4.1.1 Market Share Analysis by Geographic Region
Exhibit 4.3: Market Share Analysis by Geographic Region (2013)
4.1.2 Market Share Analysis by Selected Country
Exhibit 4.4: Market Share Analysis by Selected Country - Non-invasive Prenatal Diagnostics (2013)85

Chapter 5: Company Profiles
5.1 Sequenom Inc
Exhibit 5.1: Sequenom, Inc., Revenues by Business Segment ($ millions) 2013-2011
5.2 Ariosa Diagnostics
5.3 Natera Inc
5.4 LifeCodexx AG
5.5 Verinata Health, Inc (Illumina, Inc)
Exhibit 5.2: Illumina, Inc., Revenues by Business Segment ($ thousands) 2013-2011
5.6 Berry Genomics Co., Ltd
5.7 BGI Diagnostics (Division of BGI)
5.8 CellScape
5.9 Kellbenx

Glossary of Acronyms

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Ariosa Diagnostics
  • Sequenom Inc
  • Natera Inc
  • LifeCodexx AG
  • Verinata Health, Inc (Illumina, Inc)
  • Illumina, Inc.,
  • Berry Genomics Co., Ltd
  • BGI Diagnostics (Division of BGI)
  • CellScape
  • Kellbenx
Note: Product cover images may vary from those shown
5 of 4

Secondary Research

Typically, the secondary research process involves the use of secondary sources of information which includes internet research, the use of relevant databases, company annual reports and SEC documents and investor presentations. This process allows the collation of information on key players within the market of interest, an understanding of their products and service offerings and preliminary assessment of  the size of the market and key drivers and restraints impacting market growth. This process serves to inform appropriate market segmentation, market sizing and forecasting (bottom up and top down methodologies) and understanding of the competitive landscape.

Primary Research

Primary research involves in-depth telephone or face-to-face interviews with persons within the industries of interest. Interviews are conducted to obtain qualitative and quantitative information which is analysed to verify market sizing and forecasting and to provide insight into vital strategies deemed critical to market development. Analysts are experienced in interviewing industry experts at C-suite level and within sales and marketing and R&D functions within the biotechnology, pharmaceutical and medical device industries. For certain custom research projects, key opinion leaders across a range of therapeutic disciplines have been interviewed both through in-depth telephone interviews and on a face-to-face basis.

 

Loading
LOADING...

Adroll
adroll